An intraperitoneal injection of GK-2 (dipeptide mimetic of nerve growth factor, 0.01-5.00 mg/kg) 24 h before the adverse exposure reduced the severity of haloperidol-induced catalepsy in rats. This agent retained the activity after oral administration in a dose of 10 mg/kg. An intraperitoneal injection of GK-2 in a dose of 1 mg/kg reduced the severity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in mice. Administration of GK-2 45 min after haloperidol treatment was also followed by a decrease in the degree of catalepsy. The repeated intraperitoneal treatment with GK-2 in a dose of 1 mg/kg after intrastriatal injection of 6-hydroxydopamine was shown to prevent the development of apomorphine- induced rotations in rats.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
T. A. Voronina, E. A. Val’dman, and L. N. Nerobkova, Manual on Experimental (Preclinical) Study of New Pharmacological Agents [in Russian], Ed. R. U. Khabriev, Moscow (2005), pp. 295–307.
T. A. Gudasheva, T. A. Antipova, and S. B. Seredenin, Dokl. Akad. Nauk. Biokhim., Biofiz., Mol. Biol., 434, No. 4, 549–552 (2010).
K. B. Kurakhmaeva, T. A. Voronina, I. G. Kapitsa, et al., Byull. Eksp. Biol. Med., 145, No. 2, 221–224 (2008).
N. N. Yakhno and M. R. Nodel’, Rus. Med. Zh., 8, No. 10, 418–425 (2000).
M. A. Bruno, P. B. Clarke, A. Seltzer, et al., J. Neurosci., 24, No. 37, 8009–8018 (2004).
R. K. Chaturvedi, S. Shukla, K. Seth, and A. K. Agrawal, Neurosci. Lett., 398, Nos. 1–2, 44–49 (2006).
A. M. Colangelo, M. R. Bianco, L. Vitagliano, et al., J. Neurosci., 28, No. 11, 2698–2709 (2008).
L. Lorigados Pedre, N. Pavón Fuentes, L. Alvarez González, et al., Brain Res., 952, No. 1, 122–127 (2002).
M. Mogi, A. Togari, T. Kondo, et al., Neurosci. Lett., 270, No. 1, 45–48 (1999).
G. Paxinos and C. Watson, The Rat Brain Stereotaxic Coordinates, New York (1998).
J. C. Perry, D. C. Hipólide, S. Tufik, et al., Exp. Neurol., 195, No. 2, 322–329 (2005).
V. F. Sagach, O. V. Bazilyuk, N. N. Oleshko, et al., Neurophysiology, 30, No. 1, 13–17 (1998).
M. Salinas, R. Diaz, N. G. Abraham, et al., J. Biol. Chem., 278, No. 16, 13,898-13,904 (2003).
K. Shimoke and H. Chiba, J. Neurosci. Res., 63, No. 5, 402–409 (2001).
S. W. Jang, M. Okada, I. Sayeed, et al., Proc. Natl. Acad. Sci. USA, 104, No. 41, 16,329-16,334 (2007).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 151, No. 6, pp. 634–637, June, 2011
Rights and permissions
About this article
Cite this article
Povarnina, P.Y., Gudasheva, T.A., Vorontsova, O.N. et al. Antiparkinsonian Properties of a Nerve Growth Factor Dipeptide Mimetic GK-2 in in Vivo Experiments. Bull Exp Biol Med 151, 690–693 (2011). https://doi.org/10.1007/s10517-011-1417-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-011-1417-6